Cidara Therapeutics (CDTX) saw its stock climb after the FDA granted Breakthrough Therapy designation to CD388, its experimental treatment for flu. In addition, the company received new funding support from BARDA. This combination of developments is fueling investor confidence.

Bolstered by the FDA’s Breakthrough Therapy nod and fresh support from BARDA, Cidara Therapeutics has attracted renewed market attention. After surging more than 17% in the past week and notching a 13% gain over the last month, its momentum is hard to miss. The stock’s year-to-date share price return stands at an extraordinary 299%. Long-term holders have enjoyed a one-year total shareholder return of over 733%. All this points to a company rapidly climbing out of obscurity, with growing optimism about its drug pipeline and future prospects.

If Cidara’s recent leap has you on the lookout for other innovative biotechs, it’s a great time to discover See the full list for free.

With Cidara shares more than tripling this year but still trading nearly 46% below analyst price targets, investors are now left to weigh whether the recent surge leaves more upside or if expectations have already run too far ahead.

Price-to-Book Ratio of 5.5x: Is it justified?

Cidara Therapeutics' shares are trading at a price-to-book ratio of 5.5x, significantly higher than both its industry peers and the broader market. This premium has become more relevant as the stock has surged nearly 300% year-to-date, inviting scrutiny from investors and analysts alike.

The price-to-book ratio compares a company’s market value to its net assets. It is often used for early-stage biotech firms that lack profits but hold valuable intellectual property or partnerships. A high figure like 5.5x implies investors are pricing in aggressive expectations for future breakthroughs or substantial asset value beyond the current balance sheet.

However, Cidara’s price-to-book ratio stands notably above the US Biotechs industry average of 2.6x and is also above the peer group average of 4.1x. This suggests the stock’s valuation is stretched compared to companies with similar profiles, especially given that Cidara is still unprofitable and faces a challenging path to profitability.

Result: Price-to-Book of 5.5x (OVERVALUED)

However, risks remain if CD388 faces regulatory delays or clinical setbacks, as these issues could quickly dampen both investor sentiment and the share price.

Build Your Own Cidara Therapeutics Narrative

If you see things differently or want to investigate the numbers firsthand, you can shape your own view of Cidara Therapeutics in just a few minutes with Do it your way.

A great starting point for your Cidara Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don’t let opportunities slip by when there are so many exciting stocks within reach. Use these hand-picked tools to uncover tomorrow’s leaders, today.

• Find high-yield potential by checking out these 22 dividend stocks with yields > 3%, which offers reliable income with impressive dividend growth and solid fundamentals for your portfolio.
• Spot the boldest disruptors in tech by tapping into these 26 AI penny stocks to see which companies are setting big trends with advanced artificial intelligence breakthroughs.
• Uncover deeply undervalued names by exploring these 834 undervalued stocks based on cash flows, delivering rare opportunities based on cash flow strength where the market hasn’t caught up yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.